These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30075697)

  • 1. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
    di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
    Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necitumumab for the treatment of advanced non-small-cell lung cancer.
    Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
    Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Ciuleanu T; Socinski MA; Obasaju C; Luft AV; Szczesna A; Szafrański W; Ramlau R; Bálint B; Molinier O; Depenbrock H; Nanda S; Paz-Ares L; Thatcher N
    Clin Lung Cancer; 2018 Mar; 19(2):130-138.e2. PubMed ID: 29158123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
    Paz-Ares L; Socinski MA; Shahidi J; Hozak RR; Soldatenkova V; Kurek R; Varella-Garcia M; Thatcher N; Hirsch FR
    Ann Oncol; 2016 Aug; 27(8):1573-9. PubMed ID: 27207107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
    Reck M; Thomas M; Kropf-Sanchen C; Mezger J; Socinski MA; Depenbrock H; Soldatenkova V; Brown J; Krause T; Thatcher N
    Oncol Res Treat; 2016; 39(9):539-47. PubMed ID: 27614872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
    Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necitumumab: First Global Approval.
    Garnock-Jones KP
    Drugs; 2016 Feb; 76(2):283-9. PubMed ID: 26729188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.
    Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Nishio M; Kato T; Takahashi T; Ebi H; Aono M; Yamamoto N; Ohe Y; Nakagawa K
    ESMO Open; 2024 Apr; 9(4):102975. PubMed ID: 38520847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
    Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
    Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
    Reck M; Socinski MA; Luft A; Szczęsna A; Dediu M; Ramlau R; Losonczy G; Molinier O; Schumann C; Gralla RJ; Bonomi P; Brown J; Soldatenkova V; Chouaki N; Obasaju C; Peterson P; Thatcher N
    J Thorac Oncol; 2016 Jun; 11(6):808-18. PubMed ID: 26980471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
    Giuliani G; Grossi F; de Marinis F; Walzer S
    Lung Cancer; 2010 Aug; 69 Suppl 1():S11-7. PubMed ID: 20727457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necitumumab for non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Yamamoto N; Nishio M; Ohe Y; Kato T; Takahashi T; Kamada A; Suzukawa K; Omori Y; Enatsu S; Nakagawa K; Tamura T
    Lung Cancer; 2019 Mar; 129():55-62. PubMed ID: 30797492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
    JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
    Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
    Bischoff HG; Heigener DF; Walzer S; Nuijten M
    Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.